Piramal Pharma Limited

NSE PPLPHARMA.NS

Piramal Pharma Limited Return on Capital Employed (ROCE) for the year ending March 31, 2024: 5.72%

Piramal Pharma Limited Return on Capital Employed (ROCE) is 5.72% for the year ending March 31, 2024, a 260.24% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Piramal Pharma Limited Return on Capital Employed (ROCE) for the year ending March 31, 2023 was 1.59%, a -85.52% change year over year.
Piramal Pharma Limited Return on Capital Employed (ROCE) for the year ending March 31, 2022 was 10.97%, a -14.61% change year over year.
Piramal Pharma Limited Return on Capital Employed (ROCE) for the year ending March 31, 2021 was 12.84%.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

NSE: PPLPHARMA.NS

Piramal Pharma Limited

CEO	Mr. Peter Daniel DeYoung
IPO Date	Oct. 19, 2022
Location	India
Headquarters	507, Skyline Wealth Space
Employees	6,719
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Piramal Pharma Limited operates as a pharmaceutical company. It sells a portfolio of pharma products, as well as provides various pharma services, including injection, HPAPI, etc. The company was incorporated in 2020 and is based in Mumbai, India. Piramal Pharma Limited operates as a subsidiary of Piramal Enterprises Limited.

Key trends

Past 5 years